A Cochrane systematic review of 12 RCTs (9,547 participants) showed that, compared to placebo, aclidinium resulted in marginal improvements in quality of life and FEV 1, and reduced the number of patients with exacerbations requiring hospitalisation (NNT 77, 95% CI 51 to 233) ( Ni 2014). A number of LAMAs are available in Australia, which are delivered via a range of devices:Īclidinium: Aclidinium is a twice daily LAMA. Long-acting muscarinic antagonists (LAMAs) result in bronchodilation with a duration of action of 12 to 24 hours, depending on the agent. O1.2.1 Long-acting muscarinic antagonists (LAMA) These benefits come at a cost of increased adverse effects, which are generally of mild to moderate severity. Long-acting bronchodilators produce significant improvements in lung function, symptoms and quality of life ( Braido 2013), as well as decreasing exacerbations. All Papers Considered for Citation in COPD-X.Appendix 6: Table of Systematic Reviews Evaluating the Effect of Self-Management in COPD.Appendix 5 – Table of Minimum Clinically Important Differences (MCID).Appendix 4 – Strategies that may assist in reminding people to reduce sedentary time.Appendix 2 – Explanation of inhaler devices.Appendix 1 – Use and doses of long-term inhaled bronchodilator and corticosteroids determined in response trials.Uptake and impact of guidelines for exacerbations X3.5 Develop post-discharge plan and follow-up.Refer appropriately to prevent further deterioration (‘P’) X2.2.4 Combined systemic corticosteroids and antibiotics for treatment of exacerbation.X2.2.3 Antibiotics for treatment of exacerbations.X2.2.2 Systemic corticosteroids for treatment of exacerbations.X2.2.1 Inhaled bronchodilators for treatment of exacerbations.X2.1 Confirm exacerbation and categorise severity.D1.7 Clinical psychologist/psychiatrist.D1.3 GP practice nurse/ nurse practitioner/ respiratory educator/ respiratory nurse.P11 Long-term home non-invasive ventilation.Humidification therapy and nasal high flow (NHF) therapy P2.3 Haemophilus influenzae immunisation.P1.2.5 Electronic cigarettes (e-cigarettes).P1.2.2 Nicotine Receptor Partial Agonists.O10.3 Palliative oxygen therapy for dyspnoea.O9.2 Lung volume reduction surgery and bronchoscopic interventions.O8.1 Treatment of hypoxaemia and pulmonary hypertension.O7.13 Testosterone deficiencies and supplementation.O7.11 Combined Pulmonary Fibrosis and Emphysema.O7.8 Gastro-oesophageal reflux disease (GORD).O7.2.5 Coronary revascularisation procedures.O7.1 Increased risks from comorbidities in the presence of COPD.O6.8 Chest physiotherapy (Airway clearance techniques).O6.5 Physical activity and sedentary behaviour.O6.4 Neuromuscular Electrical Stimulation.O4.2.1 Eosinophil count and inhaled corticosteroids.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |